ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.by: Jer-Yen Y Yang, Cong S S Zong, Weiya Xia, Hirohito Yamaguchi, Qingqing Ding, Xiaoming Xie, Jing-Yu Y Lang, Chien-Chen C Lai, Chun-Ju J Chang, Wei-Chien C Huang, Hsin Huang, Hsu-Ping P Kuo, Dung-Fang F Lee, Long-Yuan Y Li, Huang-Chun C Lien, Xiaoyun Cheng, King-Jen J Chang, Chwan-Deng D Hsiao, Fuu-Jen J Tsai, Chang-Hai H Tsai, Aysegul A A Sahin, William J J Muller, Gordon B B Mills, Dihua Yu, Gabriel N N Hortobagyi, Mien-Chie C Hung
Nat Cell Biol (20 January 2008)
|
Reviews
[Write a review of this article]
There are no reviews of this article
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
AbstractThe RAS-ERK pathway is known to play a pivotal role in differentiation, proliferation and tumour progression. Here, we show that Erk downregulates Forkhead box O 3a (FOXO3a) by directly interacting with and phosphorylating FOXO3a at Ser 294, Ser 344 and Ser 425, which consequently promotes cell proliferation and tumorigenesis. The ERK-phosphorylated FOXO3a degrades via an MDM2-mediated ubiquitin-proteasome pathway. However, the non-phosphorylated FOXO3a mutant is resistant to the interaction and degradation by murine double minute 2 (MDM2), thereby resulting in a strong inhibition of cell proliferation and tumorigenicity. Taken together, our study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS-ERK and MDM2.
BibTeX record
RIS record